Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Novartis AG (NVS) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis AG (NVS) - $25 value - yours FREE >>
Image: Bigstock
Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD
Global Blood Therapeutics, Inc. announced plans to expand the label of Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in children aged 4 to 11 years, following a Type B meeting with the FDA.
In November 2019, the FDA approved Oxbryta as an oral, once-daily treatment for SCD in patients aged 12 years or above. Following this, the drug became the first and only therapy that directly inhibits sickle hemoglobin polymerization, a major cause for SCD. SCD is a chronic, inherited blood disorder that affects hemoglobin levels.
Global Blood plans to submit a New Drug Application (NDA) for Oxbryta, which will include a new, age-appropriate formulation, for the treatment of SCD in children 4 to 11 years under the FDA’s accelerated approval pathway. The NDA will include clinical data from the ongoing phase IIa HOPE-KIDS 1 study.
Shares of Global Blood have declined 17.2% so far this year against the industry’s growth of 7.9%.
The company has another pipeline candidate, inclacumab, which is a novel fully human monoclonal antibody against P-selectin, in its portfolio. The drug is being developed as a treatment for vaso-occlusive crises (“VOC”) in patients with SCD. The company is developing inclacumab with drug giant Roche Holding AG (RHHBY - Free Report) .
Last year, the FDA also approved Novartis’ (NVS - Free Report) Adakveo (crizanlizumab) to lower the frequency of VOCs or pain crises in patients with SCD, aged 16 years or above. bluebird bio (BLUE - Free Report) is also developing LentiGlobin for the treatment of VOC in patients with SCD.
Global Blood Therapeutics, Inc. Price
Global Blood Therapeutics, Inc. price | Global Blood Therapeutics, Inc. Quote
Zacks Rank
Global Blood currently has a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>